Daniel Spiegelman
2017
In 2017, Daniel Spiegelman earned a total compensation of $4.6M as Executive Vice President, Chief Financial Officer at BioMarin Pharmaceutical, a 5% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $481,380 |
|---|---|
| Option Awards | $1,439,891 |
| Salary | $559,231 |
| Stock Awards | $2,133,048 |
| Other | $28,325 |
| Total | $4,641,875 |
Spiegelman received $2.1M in stock awards, accounting for 46% of the total pay in 2017.
Spiegelman also received $481.4K in non-equity incentive plan, $1.4M in option awards, $559.2K in salary and $28.3K in other compensation.
Rankings
In 2017, Daniel Spiegelman's compensation ranked 2,098th out of 14,666 executives tracked by ExecPay. In other words, Spiegelman earned more than 85.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,098 out of 14,666 | 86th |
Division Manufacturing | 717 out of 5,770 | 88th |
Major group Chemicals And Allied Products | 194 out of 2,074 | 91st |
Industry group Drugs | 147 out of 1,730 | 92nd |
Industry Pharmaceutical Preparations | 114 out of 1,329 | 91st |
Source: SEC filing on April 23, 2019.
Spiegelman's colleagues
We found four more compensation records of executives who worked with Daniel Spiegelman at BioMarin Pharmaceutical in 2017.
2017
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
2017
Henry Fuchs
BioMarin Pharmaceutical
President, Worldwide R&D
2017
Jeff Ajer
BioMarin Pharmaceutical
Executive Vice President, Chief Commercial Officer
2017
Robert Baffi
BioMarin Pharmaceutical